Genzyme's FDA issues remain unresolved

Genzyme suffered a surprising regulatory setback in plans to expand production of its treatment for Pompe disease, after the company had issued an optimistic outlook based in part on its prediction that the expansion would be cleared. Report

Suggested Articles

Pfizer
Marketing

Pfizer's Xeljanz gets EMA blood clots warning

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

by Angus Liu
Antibiotic-resistant bacteria
Pharma

FDA approves Shionogi's Fetroja with scary mortality warning

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

by Kyle Blankenship
Asia Map
Pharma Asia

Sandoz, Lupin, Dr. Reddy's, Aslan and more—FiercePharmaAsia

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

by Angus Liu